Blue Trust Inc. Grows Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Blue Trust Inc. boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 171.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 348 shares of the company’s stock after acquiring an additional 220 shares during the quarter. Blue Trust Inc.’s holdings in Neurocrine Biosciences were worth $40,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Commonwealth Equity Services LLC increased its holdings in Neurocrine Biosciences by 0.6% in the first quarter. Commonwealth Equity Services LLC now owns 13,941 shares of the company’s stock valued at $1,923,000 after buying an additional 84 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in Neurocrine Biosciences by 0.8% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock valued at $1,574,000 after buying an additional 90 shares during the period. Fifth Third Bancorp increased its stake in Neurocrine Biosciences by 14.7% in the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock valued at $99,000 after buying an additional 92 shares during the period. Total Clarity Wealth Management Inc. increased its stake in shares of Neurocrine Biosciences by 4.3% during the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock worth $335,000 after purchasing an additional 100 shares during the last quarter. Finally, Caprock Group LLC grew its stake in Neurocrine Biosciences by 7.0% in the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock valued at $230,000 after buying an additional 109 shares during the last quarter. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Up 1.6 %

NBIX stock opened at $122.21 on Friday. The stock has a market capitalization of $12.34 billion, a P/E ratio of 32.76 and a beta of 0.36. Neurocrine Biosciences, Inc. has a 12 month low of $103.63 and a 12 month high of $157.98. The firm has a 50-day moving average price of $119.77 and a 200-day moving average price of $133.49.

Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings results on Wednesday, October 30th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.47 by ($0.23). The firm had revenue of $622.10 million for the quarter, compared to analyst estimates of $604.11 million. Neurocrine Biosciences had a net margin of 17.21% and a return on equity of 15.68%. As a group, equities analysts predict that Neurocrine Biosciences, Inc. will post 4.37 EPS for the current fiscal year.

Analysts Set New Price Targets

NBIX has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. Robert W. Baird lifted their price target on shares of Neurocrine Biosciences from $157.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, August 2nd. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a research note on Tuesday. BMO Capital Markets cut their price objective on shares of Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating on the stock in a research report on Thursday, October 17th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, Neurocrine Biosciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Insider Buying and Selling

In other news, Director William H. Rastetter sold 14,250 shares of the firm’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $146.69, for a total transaction of $2,090,332.50. Following the completion of the sale, the director now directly owns 37,491 shares of the company’s stock, valued at $5,499,554.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, Director William H. Rastetter sold 14,250 shares of Neurocrine Biosciences stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares of the company’s stock, valued at approximately $5,499,554.79. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Matt Abernethy sold 14,100 shares of Neurocrine Biosciences stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total value of $2,120,358.00. Following the transaction, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at $4,741,180.64. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,336 shares of company stock worth $7,063,652 in the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.